GD
AZN icon

Grandfield & Dodd’s AstraZeneca AZN Stock Holding History

Grandfield & Dodd’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$557K Sell
2,935
-209
-7% -$39.3K 0.03% 146
2026
Q1 		$620K Sell
3,144
-68
-2% -$13.1K 0.04% 132
2025
Q4 		$591K Buy
3,212
+23
+0.7% +$4.03K 0.03% 132
2025
Q3 		$489K Buy
3,189
+32
+1% +$4.84K 0.03% 140
2025
Q2 		$441K Sell
3,157
-95
-3% -$13.3K 0.03% 144
2025
Q1 		$478K Sell
3,252
-1
-0% -$145 0.03% 141
2024
Q4 		$426K Sell
3,253
-460
-12% -$64.4K 0.03% 150
2024
Q3 		$579K Sell
3,713
-728
-16% -$118K 0.03% 134
2024
Q2 		$693K Sell
4,441
-165
-4% -$24.8K 0.04% 120
2024
Q1 		$624K Sell
4,606
-285
-6% -$37.7K 0.04% 126
2023
Q4 		$659K Sell
4,891
-528
-10% -$68.6K 0.05% 124
2023
Q3 		$734K Sell
5,419
-434
-7% -$59.3K 0.05% 119
2023
Q2 		$838K Sell
5,853
-385
-6% -$56.6K 0.06% 111
2023
Q1 		$866K Sell
6,238
-94
-1% -$12.6K 0.06% 112
2022
Q4 		$859K Sell
6,332
-1
-0% -$125 0.06% 110
2022
Q3 		$690K Sell
6,333
-246
-4% -$31.2K 0.06% 115
2022
Q2 		$870K Hold
6,579
– – 0.07% 106
2022
Q1 		$870K Sell
6,579
-200
-3% -$24K 0.06% 114
2021
Q4 		$790K Sell
6,779
-356
-5% -$41.9K 0.05% 116
2021
Q3 		$860K Buy
+7,135
New +$831K 0.06% 109

Other funds holding AZN

EP
Evelyn Partners London $46.9B AUM
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Grandfield & Dodd's AZN Position: Q2 2026 in Review

Grandfield & Dodd reduced its AstraZeneca (AZN) stake by 6.6% in Q2 2026, selling an estimated $39.3K and leaving 2,935 shares worth $557K. The position accounts for 0.03% of the portfolio, ranked #146.

Grandfield & Dodd first reported a position in AZN in Q3 2021 and has held it in 20 quarters since. The position peaked at $870K in Q2 2022. 1,504 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • Grandfield & Dodd held 2,935 shares of AstraZeneca worth $557K as of Q2 2026.
  • Grandfield & Dodd sold 209 AstraZeneca shares in Q2 2026, an estimated $39.3K.
  • AstraZeneca made up 0.03% of Grandfield & Dodd's portfolio in Q2 2026, its #146 holding.
  • Grandfield & Dodd first reported a position in AstraZeneca in Q3 2021 and has held it in 20 quarters since.
  • Grandfield & Dodd's AstraZeneca position peaked at $870K in Q2 2022.
  • 1,504 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Grandfield & Dodd's 13F filing for Q2 2026, filed 7 Aug 2026.